Nitric Oxide Mediates Metabolic Coupling of Omentum-Derived Adipose Stroma to Ovarian and Endometrial Cancer Cells

Bahar Salimian Rizi, Christine Caneba, Aleksandra Nowicka, Ahmad W. Nabiyar, Xinran Liu, Kevin Chen, Ann Klopp, and Deepak Nagrath

Abstract

Omental adipose stromal cells (O-ASC) are a multipotent population of mesenchymal stem cells contained in the omentum tissue that promote endometrial and ovarian tumor proliferation, migration, and drug resistance. The mechanistic underpinnings of O-ASCs’ role in tumor progression and growth are unclear. Here, we propose a novel nitric oxide (NO)-mediated metabolic coupling between O-ASCs and gynecologic cancer cells in which O-ASCs support NO homeostasis in malignant cells. NO is synthesized endogenously by the conversion of L-arginine into citrulline through nitric oxide synthase (NOS). Through arginine depletion in the media using L-NAME, we demonstrate that patient-derived O-ASCs increase NO levels in ovarian and endometrial cancer cells (9). Furthermore, O-ASCs promoted proliferation, migration, chemotherapy, and radiation response of ovarian cancer cells (8). O-ASCs recruited to tumors expressed factors that enhanced tumor vasculization, promoted survival, and proliferation of endometrial cancer cells (9). However, the mechanism by which O-ASCs aid tumor growth and induce chemoresistance is unknown. We hypothesize that “nitric oxide homeostasis” is a key player in regulating reciprocal communication between O-ASCs and gynecologic cancers (ovarian cancer and endometrial cancer).

O-ASCs can differentiate into adipocytes lineage, promote tumor initiation, growth, vascularization, metastasis, and resistance to chemotherapy in many tumor models (2, 10). Recently, we showed that O-ASCs promoted proliferation, migration, chemotherapy, and radiation response of ovarian cancer cells (8). Omentum has been shown to promote colonization of ovarian cancer cells (11). Mounting evidence suggests that bidirectional communication between ovarian cancer and its microenvironment is critical for tumor growth (12). One critically important, yet often overlooked, contributor to ovarian cancer and endometrial cancer tumor growth, progression, and metastasis to omentum is nitric oxide (NO). Cancer cells’ high affinity for NO could explain the proximity of many carcinomas to fatty tissue, and thus the high positive correlation between obesity and cancer (13).

NO is an intracellular signaling molecule that plays pleiotropic roles in cellular physiology and diseases (14) by regulating cellular levels of pH, blood flow, oxygen, and nutrients (15). NO is synthesized endogenously by the conversion of L-arginine into citrulline through nitric oxide synthase (NOS). NOS is differentially expressed in obese and nonobese individuals and is overexpressed in many tumors (16, 17). It has been shown that high levels of NOS activity exist in malignant tissue from gynecologic cancers (18) and higher NOS expressions were correlated to the
more advanced stages of breast cancers (19). NO acts in a bimodal manner in cancer research, at low concentrations it increases proliferation, angiogenesis, invasiveness, metastasis, and cytoprotection (10, 20, 21). However, high concentrations of NO induce extensive DNA damage, oxidative, and nitrosative stress that lead to cytotoxicity and apoptosis of tumor cells (22, 23). The impact of altering NO metabolism in the tumor microenvironment is unknown.

Altered cancer cells’ metabolism is one of the tumor hallmarks (24). Warburg reported that cancer cells rely on glycolysis for their energetic needs even under aerobic conditions. Despite glycolysis being an inefficient mechanism for ATP production compared with mitochondrial tricarboxylic acid (TCA) cycle, cancer cells were found to be metabolically reprogrammed for increased glucose uptake and pyruvate toward lactate secretion. Treating cancer as an isolated epithelial cell disease has not been successful because of the unique interplay between the various aspects of the tumor and microenvironment (25). Thus, the microenvironment has been the recent target of molecular strategies for tumor treatment (12).

Little is known about the features of metabolic alterations induced by O-ASCs in cancer cells. We hypothesize that O-ASCs regulate NO metabolism in ovarian cancer and endometrial cancer cells, thereby support tumor growth, survival, and chemoresistance. We propose a previously unexplored metabolic coupling among ovarian cancer, endometrial cancer cells, and O-ASCs by showing that O-ASCs affect cancer hallmarks by altering the NO homeostasis. Furthermore, we demonstrate that patient-derived O-ASCs regulate NO homeostasis in ovarian cancer and endometrial cancer cells and promote tumor growth and induce chemoresistance in these cancer cells. Collectively, our study will lead to significant advances in the understanding of the omentum in altering cancer metabolism and lead to novel therapies, enabling treatment disrupting the communication between the tumor and omentum.

Materials and Methods

Isolation of patient-derived O-ASC

Grossly normal-appearing human omentum was obtained according to Institutional Review Board–approved protocols. O-ASCs were isolated as described in previously published protocol (8). Informed consent for tissue banking was obtained from each patient. All clinical investigations were conducted according to the principles expressed in the Declaration of Helsinki. Written consent was obtained from each patient. O-ASCs were classified as lean (BMI≤25) and overweight (BMI≥25). ASCs were isolated according to published protocols (24). After isolation, cells were expanded in vitro, and then characterized with flow cytometry to evaluate cell-surface marker expression. O-ASCs were characterized with antibodies against the following markers: CD34, CD44, CD45, CD29, CD90, EpCam (from Becton Dickinson), and CD105 (from BioLegend).

Cells and reagents

The human ovarian and endometrial carcinoma cell lines, OVCAR429 and HEC-1-A, were grown in RPMI-1640 containing 10% fetal bovine serum and 2% penicillin and streptomycin mixture. O-ASCs were maintained in MEM-α containing 20% fetal bovine serum and 1% penicillin and streptomycin. All cells were kept at 37°C in a humidified atmosphere of 5% CO₂, N₂–nitro-arginine methyl ester (L-NAME) and SNAP were pur-chased from Enzo Life Sciences. L-arginine from bovine was obtained from Sigma-Aldrich.

Direct and indirect coculture

For indirect cocultures, transwell plates (Corning) with two compartments separated by a polycarbonate membrane with 0.4-μm pores were used. O-ASCs were seeded in the upper compartment (0.2 × 10⁵ cells/well) and cancer cells in the lower compartment (1 × 10⁵ cells/well). O-ASCs and cancer cells could not contact each other directly although they can communicate through the soluble factors derived from each cell type such as metabolites and growth factors. The cells were cocultured for 2 to 5 days, depending on experiments. Cancer cells and O-ASCs alone were cultured as controls.

For direct coculture, O-ASCs were seeded in 96-well microplates and incubated at 37°C until they attached to surface. Next, cancer cells were seeded on top of attached O-ASCs. The ratio of O-ASCs to cancer cells was 3:1.

Quantitative analysis of NO

Cancer cells either experienced transwell coculture of O-ASCs or they were monocolonized for 72 hours. The media were replaced with fresh media (RPMI-1640) 3 hours before sample collection. For measurement of NO content in homogenates, cells were washed in PBS solution at 4°C and lysed in PBS solution containing 1% Nonidet P-40, 2 mM/L N-ethylmaleimide, 0.2 mM/L diethyleneetriaminepentaacetic dihydrade, and protease inhibitors. After three instant freeze–thaw cycles (~80°C), lysates were passed through a 29-gauge needle to reduce viscosity and spun at 2,000 × g for 10 minutes at 4°C. Protein concentration was measured to normalize the NO results. Samples were assessed by using a Siemens NO analyzer (280i; GE Analytical Instruments).

Cell viability analysis

OVCAR429 and HEC-1-A were cocultured either directly or indirectly with O-ASCs at 37°C for 2 to 5 days, depending on the experiment. For indirect coculture, cancer cells were trypsinized and stained with Trypan Blue. Viable cancer cells were quantified by hemocytometer counting. For direct coculture experiments, OVCAR429 and HEC-1-A cells stably transfected with firefly luciferase gene using a lentiviral method were used. Cancer cells’ viability and proliferation was determined by measuring luminescence by a plate reader (SpectraMax M5; Molecular Devices).

UPLC

Cell supernatants were collected after 24 hours of incubation with fresh media and were stored at ~80°C until further analysis. Extracellular metabolite profiling was performed using a Waters ACQUITY ultra-performance liquid chromatography (UPLC) system. Derivatization of samples was according to the manufacturer’s instructions. Briefly, deproteinized samples are prepared by mixing 1:1 ratio of collected media with 10% sulfosalicylic acid/norvaline solution. The mixture is centrifuged for no more than 5 minutes at a fixed angle at 13,000 rpm. Supernatant from the centrifugation is then added to borate/NaOH mixture along with reconstituted MassTrak AAA regent. Chromatographic separations were performed on a 2.1 mm × 150 mm chromatography column. The column was maintained at 43°C, eluted with a mix of 99.9% of MassTrak AAA eluent A concentrate (8%–10% acetonitrile, 4%–6% formic acid, 84%–88% ammonium acetate/water solution), and diluted at 10% in miliQ water and 0.1% of MassTrak AAA eluent B (≥95% acetonitrile, ≤5% acetic acid).
Acid) with a MassTrak AAA eluent B (≥95% acetonitrile, ≤5% acetic acid derivatized sample was injected into the column with UV detection at 260 nm.

Adipogenesis
O-ASCs were cultured in a 12-well plate in MEM-α media until cells were almost confluent. The media were changed with quick differentiation media that includes DMEM/F12, human transferrin (10 µg/mL), insulin (0.02 µmol/L), cortisol (0.1 µmol/L), rosiglitazone (1 µmol/L), dexamethasone (1 µmol/L), IBMX (500 µmol/L), and indomethacin (200 µmol/L); all were purchased from Sigma-Aldrich). After 4 days, the media were changed to adipogenic media including insulin (0.02 µmol/L) and rosiglitazone (1 µmol/L). Differentiation of O-ASCs was determined by either OilRed O staining or measuring glycerol 3-phosphate dehydrogenase (G3PDH) activity.

OilRed O staining
The cells incubated in adipogenic media for 7 or 14 days (depending on the experiment) were rinsed twice with warm PBS. The cells were fixed with 5 vol% glutaraldehyde solution in PBS for 20 minutes at room temperature. The oil red O solution was prepared by mixing an oil red O (0.5 wt%) stock solution in isopropanol (6 mL) and 4-mL distilled water followed by the filtration through Whatman filter (No. 1). Fixed cells were incubated with oil red O for 10 minutes at room temperature. The cells were rinsed with tap water to be viewed by phase-contrast microscopy (EYOS XI Core Cell Imaging System).

G3PDH activity
O-ASCs were grown and induced to differentiate in 12-well plate as describe above. The G3PDH activity was measured using the method by Sottile and Sewnen (26). Briefly, the media were removed and the cells were washed once with PBS. An ice-cold homogenization solution was then added (20 mmol/L Tris, 1 mmol/L EDTA, 1 mmol/L β-mercaptoethanol, and pH adjusted to 7.3). Cell lysate was stored at −20°C until measurement. To prepare the enzyme reaction, 80 µL of reaction mix (0.1 mol/L triethanolamine, 2.5 mmol/L EDTA, 0.1 mmol/L β-mercaptoethanol, 334 mmol/L NADH, and pH adjusted to 7.7) and 10 µL of cell lysate were added to each well, and plates were preincubated for 10 minutes at 37°C. Dihydroxyacetone phosphate (DHAP) was added to start the reaction (10 µL/well of a 4 mmol/L stock solution in H₂O). Absorbance (340 nmol/L) was monitored at time intervals by a plate reader (SpectraMax M5; Molecular Devices). The protein content of cell cultures was determined in parallel wells. Results are expressed as mU/mg protein (1 U = 1 µmol NADH/min). For control experiments, G3PDH from human was used (Abcam).

XF bioenergetics assay
Mitochondrial oxygen consumption was measured with an XF24 Extracellular Flux Analyzer (Seahorse Bioscience). Cancer cells were reseeded upon termination of indirect coculture with O-ASCs in Seahorse 24-well microplates at a cell density of 0.5 × 10⁵ cells per well. The plate is incubated at 37°C with 5% CO₂ until cells were attached to surface. The attached cells were washed with 200 µL of assay media (FBS excluded RPMI) and were incubated at 37°C without CO₂ for 1 hour for equilibrium. The endogenous respiration or basal oxygen consumption rate (OCR) was then measured. The endogenous coupling degree of the OXPHOS system was assessed using oligomycin (2 µg/mL), an inhibitor of the F₁F₀-ATP synthase. The uncoupled OCR was also measured in the presence of 1 µmol/L of FCCP. Finally, the cells were treated with a mitochondrial complex I inhibitor, rotenone (2.5 µmol/L), to assess the mitochondrial contribution to OCR.

Metabolic assays
The lactate secretion was quantified with the lactate kit (Trinity Biotech). The lactate secreted into the growth media by the cells after 24 hours of incubation was measured according to the manufacturer’s instructions. The absorbance at 540 nm was proportional to the lactate concentration in the sample. The results were expressed in µmol/million cells. By a similar method, the glucose consumption was determined with the Glucose AutoAnalyzer kit (Wako).

The pyruvate uptake was estimated spectrophotometrically by measuring the remaining pyruvate in growth media after 24 hours of incubation of the cells in different experimental conditions as specified in the text. The aim of this assay was to determine the amount of NADH oxidized at 340 nm in a 96-well plate format. Each well contained 20 µL of sample, NADH reagent, and lactate dehydrogenase reconstituted at 50% in glycerol and diluted to 1:20 in Tris (0.1 mol/L; pH 7).

ATP measurements
The intracellular ATP content was measured using the CellTiter-Glo Luminescent Cell Viability Assay (Promega). The cells were seeded in 96-well plates upon termination of transwell coculture at 0.5 × 10⁵ cells per well and incubated at 37°C with 5% CO₂ until cells are attached to surface. Next, cells were incubated for 3 hours in the absence or the presence of oligomycin (2 µg/mL) and 2-deoxyglucose (100 mmol/L) at 37°C. The ATP content was measured in parallel wells. Results are expressed as nM/million cells.
thereby measured according to the manufacturer’s instructions, with a spectrophotometer SpectraMax M5 (Molecular Devices).

Detection of intracellular reactive oxygen species

The generation of reactive oxygen species (ROS) was determined using the ROS-specific fluorescent dye H2DCF-DA. Briefly, cancer cells and O-ASCs were transwell cocultured for 3 days. Cancer cells were trypsinized and re-plated in 96-well plates until cells were attached to surface. Next, cells were washed with PBS and incubated with 10 μmol/L H2DCF-DA for 20 minutes at 37°C. The probe was washed by PBS and the DCF-fluorescence (Ex 485 nm and Em 535 nm) was measured by a plate reader (SpectraMax M5; Molecular Devices).

NADPH measurement

A water-soluble tetrazolium salt was used to monitor the amount of nicotinamide adenine dinucleotide phosphate (NADPH) in cancer cells through its reduction to a yellow colored water-soluble formazan dye. Briefly, cells were washed with PBS and incubated with 100 μL of XTT/1-methoxyPMS solution (251 and 0.5 mmol/L, respectively) was added in each well. Formazan formation was quantified by measuring absorbance at 650 nm using a plate reader (SpectraMax M5; Molecular Devices).

Analysis of gene expression using real-time PCR

Cells from transwell coculture and monoculture were used. Total RNA was isolated using an RNeasy mini kit (QIagen). cDNA was synthesized from 1.0 μg of total RNA with the High Capacity cDNA Reverse Transcription Kit (Applied Biosystems) using a Veriti 96-well Thermal Cycler (Applied Biosystems). The mRNA levels of gene of interest were examined by real-time PCR using 50 ng of the resultant cDNA. Real-time PCR was performed with the SYBR Green PCR Master Mix (Applied Biosystems) using the StepOnePlus Real-Time PCR System (Applied Biosystems). The reactions with gene of interest were normalized against glyceraldehyde-3-phosphate dehydrogenase (GAPDH). Specific primer sets were as follows listed S’-3’; forward and reverse, respectively): iNOS, AGATAAGTGACTAATAGTACC and CATCTGCCTGGCTTGGTG; AP2, GCATGGCCAACCTAACATGA and CCTGGCCAGATGAGGAAA; and LPL, CTGGACGGGAACAGGACTCGG. Reactions were performed in a volume of 20 μL.

Data analysis

Results are expressed as mean ± SEM of at least triplicates. Statistical analyses were performed for multiple comparisons with one-way ANOVA with Dunnett post hoc tests and Bonferroni. The Student t test was implemented for two comparison analyses. Differences were considered statistically significant at P<0.05 (*, P<0.01; †, P<0.05; ‡, P<0.01; and §, P<0.001).

Results

O-ASCs induce NO synthesis in ovarian cancers and endometrial cancers

We hypothesized that “NO homeostasis” is a key player in regulating reciprocal communication between O-ASCs and cancer cells. We tested NO levels in coculture media supernatants of O-ASCs and ovarian cancer cells (Fig. 1A) as compared with tumor cells cultured alone. Significantly higher NO was detected in cocultures. To further confirm the increased NO levels in cancer cells, we measured NO in cancer cell homogenates. Indeed, NO levels were higher in cell homogenates of cancer cells that were in cocultures compared with cancer cells cultured alone (Fig. 1A). Interestingly, control cell line (IMR-90, human fibroblasts) was unable to increase NO synthesis in cocultures (Fig. 1B). These results suggest that O-ASCs selectively increase NO synthesis in cancer cells. Furthermore, O-ASCs increased expression of iNOS in HEC-1-A cells in Transwell cocultures (Fig. 1C). Cancer cells in turn increased NO synthesis in O-ASCs; O-ASCs synthesized higher NO when transwell cocultured with ovarian cancer and endometrial cancer cells (Fig. 1D).

To confirm that NO synthesis in these cells is by conversion of arginine into citrulline through NOS, we measured NO levels in the presence of NOS inhibitor L-NNAME (Fig. 1E). As seen in Fig. 1E, L-NNAME reduced the NO production in a dose-dependent manner in cancer cells. The hydrolysis of L-NNAME results in L-NNA, a fully functional inhibitor of NOS. iNOS-L-NNAME action on NOS was further confirmed using L-NNA, an active form of the NOS inhibitor. Furthermore, D-NNAME, an inactive enantiomer of L-NNAME that served as negative control, was ineffective in reducing the NO production in cancer cells. To ascertain whether arginine is a major source for NO synthesis in these cells, we measured NO synthesis under arginine depletion conditions with and without L-NNAME. As seen in Fig. 1F, under arginine-deprived conditions, NO synthesis is drastically reduced, thus indicating that other nutrients contribute toward NO synthesis is negligible. Moreover, when L-NNAME is added to inhibit NO production through endogenously synthesized arginine, the decrease of NO levels was not significant. To confirm whether arginine levels in cancer cells were regulated through arginase, an enzyme that converts arginine into ornithine and urea, we measured urea secretion in these cells.

Figure 2.

O-ASCs positively regulate ovarian cancers and endometrial cancer growth through arginine. A, O-ASCs and stably luciferase transfected ovarian cancer and endometrial cancer cells were in contact cocultures in 96-well plate. Luciferin (150 μmol/L) was added and luminescence was assessed to quantify viable cells for 5 days. The media were changed to RPMI after each measurement for further viability assessment. B, OVCAR429 and HEC-1-A cells were seeded in 6-well plates, while O-ASCs were seeded on top of transwell inserts. The media were changed to RPMI without arginine during 3 days of indirect coculture. Cancer cells' viability was measured and was reported in million units. Cancer cells without cocultures are shown in white (medium with arginine) and black (medium without arginine) bars. Cocultured cancer cells (both OVCAR429 and HEC-1-A) are labeled according to the O-ASCs they were cocultured. Cancer cells without coculture were used as the control.

Statistical analyses were performed for multiple comparisons with one-way ANOVA with Dunnett post hoc tests and Bonferroni. The Student t test was implemented for two comparison analyses. Differences were considered statistically significant at P<0.05 (*, P<0.01; †, P<0.05; ‡, P<0.01; and §, P<0.001). Multiple comparisons versus a control group were analyzed by the Dunnett method. All pairwise multiple comparisons were analyzed by the Bonferroni method.
Cancer Res; 75(2) January 15, 2015

results show that cancer cells have negligible arginase activity as measured through urea secreted in the medium (Supplementary Fig. S1A). Furthermore, gene expression analysis using the Oncomine database (27) showed that arginase-1 (ARG1) expression in ovarian and endometrial cancers was similar to normal ovarian epithelium (Supplementary Fig. S1B). The urea secretion data were in line with The Cancer Genome Atlas (TCGA) data that did not show any upregulation of arginase gene expression (ARG1) in cancer cells.

We next sought to determine whether NO regulates cancer proliferation. We used S-nitroso-N-acetyl-DL-penicillamine (SNAP), a NO donor, with varying concentrations to investigate NO's effect on cancer cell growth under complete media conditions. Our results illustrate that SNAP plays a bimodal role in the growth of ovarian cancers and endometrial cancers. At low concentrations of SNAP (less than 0.1 μmol/L), increased growth of cancer cells (Fig. 1G), whereas higher concentrations of SNAP (greater than 1 μmol/L) have cytotoxic effects. To confirm NO's role in increasing proliferation, we used low to high concentrations of l-NAME. As seen in Fig. 1H, l-NAME and l-NNA had similar behavior at low concentrations (<1 mmol/L) where they marginally reduced viability. On the contrary, both l-NNA and l-NAME significantly reduced viability at 10 mmol/L concentration compared with d-NAMe control.

O-ASCs positively regulate ovarian cancer and endometrial cancer cells growth through arginine

To understand O-ASC's role in regulating cancer cells growth, we first cultured ovarian cancers and endometrial cancers cells with and without O-ASCs cocultures for 5 days (Fig. 2A). O-ASCs increased the proliferation of both endometrial (HEC-1-A) and ovarian (OVAR429) cancer cell lines. Next, to elucidate a precise role for the NO pathway in O-ASC–induced tumor pathogenesis, we cocultured ovarian cancer and endometrial cancer cells under complete media and arginine-deprived conditions (Fig. 2B). Cells cultured under arginine-deprived conditions will have reduced NO synthesis. We found that ovarian cancer and endometrial cancer cells are arginine-dependent and hence had reduced proliferation. Significantly, transwell cocultures of both overweight and lean O-ASCs with HEC-1-A and OVAR429 cells rescued the proliferation rate in these cells under arginine-deprivation conditions. Interestingly, the rescue of proliferation was higher when cancer cells were cocultured with overweight O-ASCs compared with their lean counterparts. Similar results were obtained when cancer cells were cultured in conditioned media obtained from lean and overweight O-ASCs (Supplementary Fig. S2A). As seen in the figure, the rescue effect with conditioned media for both lean and overweight O-ASCs is less pronounced compared with rescue of proliferation obtained with transwell cocultures. We further confirmed the effect of O-ASCs in rescuing proliferation under arginine-deprivation conditions under direct contact cocultures (Fig. 2C). Interestingly, control cell line was ineffective in rescuing the reduced proliferation in cancer cells under arginine-deprivation conditions. In line with these findings, IMR-90 was found to be arginine-dependent for proliferation (Supplementary Fig. S2B). This is in contrast to complete media conditions where IMR-90 cells did increase proliferation of cancer cells.

To establish whether the O-ASC–mediated rescue under arginine deprivation is through the secreted arginine, we measured arginine using UPLC in spent media of transwell cocultures of O-ASCs and cancer cells under arginine-deprivation conditions (Fig. 2D). As seen in the figure, both lean and overweight O-ASCs had significant arginine secretion in coculture with both ovarian and endometrial cancer cells, while tumor cells alone did not secrete arginine. Interestingly, cancer cells exhibited reciprocal effect by increasing arginine synthesis from O-ASCs (Fig. 2E). As seen in the figure, arginine secretion from O-ASCs is higher when they were cocultured with cancer cells.

Inhibition of endogenous NO synthesis abrogates elevated viability of cancer cells induced by O-ASCs

The above experiments demonstrated that O-ASC coculture rescued the growth-inhibitory effect of arginine depletion. We further investigated whether O-ASCs secrete arginine, an essential metabolite for NO synthesis, or they secrete factors that upregulate NO synthesis in cancer cells. To assess whether O-ASCs secrete arginine under arginine-deprivation conditions, we added l-arginase, an enzyme that converts arginine to ornithine and urea, in direct cocultures of O-ASCs and cancer cells seeded in a ratio of 3:1. We first evaluated the efficacy of arginase in depleting arginine in the medium (Supplementary Fig. S3). As seen in the figure, arginine levels decreased with increasing arginase concentration. The l-arginase treatment depletes secreted arginine and thereby disrupts the rescue effect of O-ASCs. Indeed, l-arginase (10 U/mL) disrupted the rescue potential of O-ASCs, thus suggesting that O-ASCs secreted arginine is the possible cause behind the rescue potential of O-ASCs (Fig. 3A and B). We added l-NAMe to transwell cocultures (Fig. 3E and F). In agreement with l-arginase results, the addition of l-NAMe decreased the rescue effect of O-ASCs on cancer cells' proliferation in cocultures, thereby suggesting that O-ASCs effects on cancer cell proliferation are mediated by NO signaling. Interestingly, overweight O-ASCs had stronger rescue effect in cocultures for both ovarian and endometrial cancer cells. To determine whether the O-ASCs effect on cancer cell proliferation is mediated by secreted factors, we added l-NAMe to transwell cocultures (Fig. 3E and F). In agreement with l-arginase results, l-NAMe addition significantly reduced proliferation in cocultures. To further demonstrate the direct involvement of the NO pathway in rescue of cancer cells growth, we added SNAP (100 nmol/L), a NO donor, under arginine-deprivation and NOS-inhibition conditions (using l-NAMe; Fig. 3G). Remarkably, SNAP rescued the reduced proliferation of cancer cells under both conditions and the rescue effect was similar to O-ASC–induced rescue of cancer cell growth under l-NAMe and arginine-deprivation conditions.

Citrulline induces adipogenesis of O-ASCs

Cells with high NOS activity convert arginine into citrulline and release NO. In our previous study, we found that ovarian cancer cells secreted citrulline, suggesting significant levels of NOS activity. Thus, we measured citrulline in spent media from transwell cocultures. Interestingly, we found high levels of citrulline in cocultures compared with tumor cells alone (Fig. 4A). These results suggest that cancer cells use arginine from the tumor microenvironment and in turn secrete citrulline to alter the tumor microenvironment. To reveal the reciprocity of cancer cells in modulating O-ASCs, we hypothesized that cancer cells secrete...
Inhibition of NO synthesis abrogates elevated viability of cancer cells induced by O-ASCs. A and B, stably luciferase transfected ovarian cancer and endometrial cancer cells (OVCAR429 and HEC-1-A) were cocultured in direct contact with O-ASCs for 3 days (seeding ratio of 1:3). L-arginase (10 U/mL) was added to cancer cells without coculture and without L-arginase treatment were used as a control. C and D, L-NAME (20 mmol/L) was added to inhibit NO synthesis by blocking NOS. Cancer cells and O-ASCs were cocultured in direct contact for 72 hours with L-NAME. All the conditions were compared with cancer cells without coculture and without L-NAME treatment. E and F, cancer cells were seeded in 6-well plates while O-ASCs were on top of transwell inserts (the ratio was 1:2, respectively). G, SNAP (100 mmol/L) and L-NAME (10 mmol/L) were simultaneously added to cancer cells for 48 hours, and the results were compared with the viability of cells treated with L-NAME alone. Moreover, arginine was excluded from the cancer media, and the results were compared with cancer cells without coculture and without L-arginase treatment. H, O-ASC 1 was used as a control. I and J, O-ASC 2, O-ASC 3, and O-ASC 4 were used as a control. The Dunnett method was implemented to compare multiple groups versus a control group. Comparisons of lean and obese results were analyzed by the Bonferroni test.

Figure 3.

Inhibition of NO synthesis abrogates elevated viability of cancer cells induced by O-ASCs. A and B, stably luciferase transfected ovarian cancer and endometrial cancer cells (OVCAR429 and HEC-1-A) were cocultured in direct contact with O-ASCs for 3 days (seeding ratio of 1:3). L-arginine (10 U/mL) was added to deplete arginine from media. Luciferin (150 μg/mL) was added to cells and luminescence was assessed to determine viability of cancer cells. Cancer cells without coculture and without L-arginase treatment were used as a control. C and D, L-NAME (20 mmol/L) was added to inhibit NO synthesis by blocking NOS. Cancer cells and O-ASCs were cocultured in direct contact for 72 hours with L-NAME. All the conditions were compared with cancer cells without coculture and without L-NAME treatment. E and F, cancer cells were seeded in 6-well plates while O-ASCs were on top of transwell inserts (the ratio was 1:2, respectively). The media were changed to RPMI without arginine, with and without L-NAME (20 mmol/L), during 3 days of indirect coculture. OVCAR429 and HEC-1-A without coculture and without L-NAME treatment were used as control. G, SNAP (100 mmol/L) and L-NAME (10 mmol/L) were simultaneously added to cancer cells for 48 hours, and the results were compared with the viability of cells treated with L-NAME alone. Moreover, arginine was excluded from the cancer media, and the results were compared with arginine-free media containing SNAP (100 mmol/L). Data are expressed as mean ± SE; n > 9. *, P < 0.05; †, P < 0.01; and $, P < 0.001. The Dunnett method was implemented to compare multiple groups versus a control group. Comparisons of lean and obese results were analyzed by the Bonferroni test.

citulline that could induce adipogenesis. To confirm the hypothesis, we cultured O-ASCs in the presence of citulline for 48 hours and measured the citulline content in the spent media using UPLC. Both lean and overweight O-ASCs uptake exogenous citulline when cultured in the media supplemented with citulline (Fig. 4B). We monitored the growth rates of O-ASCs in the
A

Citrulline secretion (μmol/million cells)

O-ASC 1
O-ASC 10
O-ASC 28
O-ASC 34
O-ASC 35
O-ASC 15
O-ASC 21
O-ASC 22
O-ASC 33

Lean
Overweight

B

Cell seeding

Day 0
Day 2
Supernatant collection
for amino acid analysis

Citrulline (0.5 mmol/L)

C

O-ASC 1
O-ASC 21
O-ASC 35

Without citrulline
With citrulline (0.5 mmol/L)
Without citrulline
With citrulline (0.5 mmol/L)
Without citrulline
With citrulline (0.5 mmol/L)

D

G3PDH activity (×10^3 mU/mg protein)

W/O induction
W/ induction

O-ASC 1
O-ASC 21
O-ASC 35

Day 7
Day 14

E

Fold change

W/O induction
W/ induction

W/O citrulline
W/ citrulline

O-ASC 21 (Day 14)

F

G3PDH activity (×10^3 mU/mg protein)

W/O induction
W/ induction

O-ASC 1
O-ASC 21
O-ASC 35

W/O citrulline
W/ citrulline

OVCAR429 CM

G

G3PDH activity (×10^3 mU/mg protein)

W/O induction
W/ induction

O-ASC 1
O-ASC 21
O-ASC 35

W/O citrulline
W/ citrulline

OVCAR429 CM

Published OnlineFirst November 25, 2014; DOI: 10.1158/0008-5472.CAN-14-1337
Citrulline induces adipogenesis of O-ASCs. A, OVCAR429 and HEC-1-A cells were transwell cocultured in arginine-free media for 3 days. Fresh media were replaced every 24 hours before sample collection. Citrulline contents of collected samples were analyzed by UPLC. Cancer cell viability was measured and reported in million units to normalize the results. Cancer cells without coculture were used as a control. B, O-ASCs were incubated with MEM-media including only rosiglitazone (2 µmol/L) and L-arginine as a metabolic uncoupler; Fig. 5A). We next measured OCR under NO inhibition conditions. Consistent with previous results, adding L-NAME increased OCR (Fig. 5D). Furthermore, cocultures of both lean and overweight O-ASCs decreased OCR. Thus, from these data, we can conclude that O-ASCs increase NO synthesis in cancer cells, resulting in suppression of mitochondrial respiration in these cells.

O-ASCs regulate ovarian cancers and endometrial cancers’ metabolism via NO pathways
To expand our findings on O-ASCs’ regulation of cancer cells’ metabolism, we examined O-ASCs’ effect on the glycolysis. NO increased glucose uptake and lactate secretion in cancer cells (Fig. 6A). Both lean and overweight O-ASCs increased glycolysis in cancer cells under coculture conditions in the absence of arginine. These results confirm that O-ASCs induced NO-induced changes consistent with the Warburg effect in these cells. Interestingly, pyruvate uptake was increased in cancer cells cocultured with O-ASCs (Supplementary Fig. S4A). To investigate whether there was reciprocal communication between cancer cells and O-ASCs in regulating metabolism, we measured metabolic activity of O-ASCs with and without cocultures of cancer cells. Interestingly, O-ASCs from cancer cells coculture had higher glucose uptake and lactate secretion (Supplementary Fig. 4B). However, pyruvate uptake was reduced in O-ASCs that were cocultured with cancer cells (Supplementary Fig. S4C). In line with results previously reported, our results suggest that cancer cells transform the microenvironment cells by increasing their glucose metabolism (29). To further confirm NO’s regulation of cancer cells’ metabolism in...
Figure 5.
O-ASCs modulate cancer cells’ mitochondrial bioenergetics. A, cancer cells were seeded in XF-Seahorse multiwell plates and were incubated overnight until cells were attached to the surface. Cancer cells OCR levels were measured after treating cancer cells with SNAP (100 nmol/L), exogenous L-arginine (15 mmol/L), and L-NAME (10 mmol/L) for 3 hours before assay execution. B and C, cancer cells were reseeded in XF-seahorse multiwell plates after 3 days of transwell coculture with O-ASCs. The media of coculture did not include arginine and cells were reseeded with diluted (1:1) coculture media. Oligomycin (2 µg/mL), FCCP (1 µmol/L), and rotenone (1 µmol/L) were injected through the cartridge ports. Cells were lysed and quantified for their protein contents and used for normalization of data. D, cancer cells from transwell cocultures were injected with L-NAME (20 mmol/L) in the cartridge. Data are expressed as mean ± SE; n > 6. *, P < 0.05; †, P < 0.01; and ‡, P < 0.001. All pairwise multiple comparisons were analyzed by the Bonferroni test. The Dunnett method was implemented to compare multiple groups versus a control group.
O-ASCs regulate ovarian cancer and endometrial cancer cells metabolism via NO pathways. OVCAR429 and HEC-1-A were indirectly cocultured with O-ASCs for 3 days. The control cells from monoculture were seeded at the same time as cells with transwell coculture. Similar culture methods were used for cells in coculture and monocultures. The culture media were RPMI-1640 without arginine during 3 days of indirect coculture. Cocultured media were collected on the third day and diluted (1:1) with fresh RPMI (without arginine). Cancer cells were incubated with diluted media for 24 hours before supernatant collection.

Collected samples were analyzed for their extracellular metabolites content. A, glucose uptake and lactate secretion of cancer cells. B, cancer cells from transwell cocultures of O-ASCs were reseeded with diluted media in 96-well plates. The cells were incubated at 37°C overnight until cells are attached to the surface. Oligomycin (2 μg/μL) or 2-DG (100 mmol/L) was added 3 hours before assay execution. Glycolysis and mitochondrial ATP contribution were assessed with these inhibitors. Cancer cells without coculture and without arginine were used as control. Cancer cells from transwell cocultures of O-ASCs were reseeded and assessed for NADPH (C) and ROS (D) levels. E, schematic illustrates reciprocal interaction between cancer cells and O-ASCs before and after coculture.

Data are expressed for each cell type as the mean ± SE; n = 3 ± 1, P < 0.05, *, P < 0.01; and #, P < 0.001. The Dunnett method was used to compare multiple groups versus a control group.

cocultures, we measured glycolytic and mitochondrial ATP contribution using oligomycin (inhibits electron transport chain) and 2-DG (inhibits glycolysis), respectively. Consistent with the above results, we found that O-ASCs increased the glycolytic ATP generation but decreased the mitochondrial ATP generation in both ovarian cancer and endometrial cancer cells (Fig. 6B). Because cancer cells may divert increased glucose to the pentose phosphate pathway for NADPH generation to decrease ROS, we next measured NADPH. We found that NO increased NADPH synthesis (Fig. 6C) and decreased ROS (Fig. 6D). Notably, O-ASCs

Published OnlineFirst November 25, 2014; DOI: 10.1158/0008-5472.CAN-14-1337
Relative viable OVCAR429

W/ arginase (10 U/mL)
W/O arginase

W/ arginase (10 U/mL)
W/O arginase

W/ arginase (10 U/mL)
W/O arginase

HEC-1-A cocultured w/ O-ASC S21

HEC-1-A cocultured w/ O-ASC S33

HEC-1-A cocultured w/ O-ASC S35

OVCAR429 cocultured w/ O-ASC S21

OVCAR429 cocultured w/ O-ASC S33

OVCAR429 cocultured w/ O-ASC S35

W/ L-NAME (20 mmol/L)
W/O L-NAME

W/ L-NAME (20 mmol/L)
W/O L-NAME

W/ L-NAME (20 mmol/L)
W/O L-NAME

Paclitaxel (nmol/L)

Paclitaxel (nmol/L)

Paclitaxel (nmol/L)

Viability (ALU×10³)

Lean

Overweight

Cancer Res; 75(2) January 15, 2015
Cancer Research

Downloaded from cancerres.aacrjournals.org on May 28, 2017. © 2015 American Association for Cancer Research.
increased NADPH and reduced ROS in cocultures under arginine-deprivation conditions. These results substantiate the role of O-ASC–secreted factors that modulate NO homeostasis in cancer cells and thereby upregulate glycolysis and reduce oxidative stress (30).

O-ASCs induce chemoresistance of cancer cells

The above results show that O-ASCs secrete factors that modulate NO homeostasis and increases cancer cells’ proliferation and alters cancer metabolism. We recently showed that O-ASCs induce chemoresistance in cancer cells (8). Here, we asked whether this O-ASC–mediated chemoresistance can be deregulated by disrupting NO homeostasis. We added l-arginase in direct-contact cocultures of O-ASCs and cancer cells. The l-arginase depletes any secreted arginine by O-ASCs and blocks NO synthesis in cancer cells. Remarkably, we found that addition of l-arginase to direct-contact cocultures increased chemosensitivity of paclitaxel in cancer cells (Fig. 7A). Furthermore, addition of l-NAME in direct-contact cocultures also had similar effect and increased sensitivity of paclitaxel in cancer cells (Fig. 7B). Similar results were obtained with additional O-ASCs patient samples treated with l-arginase at 10 μM (Fig. 7C). To confirm the involvement of NO in increasing resistance of cancer cells to paclitaxel, we added SNAP in cancer cells cultured with either l-arginase or l-NAME in the presence and absence of paclitaxel (Supplementary Fig. S5). We found that SNAP decreased sensitivity of cancer cells to paclitaxel, thus corroborating our previous results. We further evaluated whether combinatorial addition of l-NAME and l-arginase will have synergistic effect in disrupting the NO-mediated communication between O-ASCs and cancer. Indeed, adding both l-NAME and l-arginase significantly reduced the cell viability in cancer cells in cocultures with O-ASCs (Fig. 7D). These results suggest that a combined approach of targeting secreted arginine through l-arginase, along with targeting microenvironment-secreted factors induced increased NO synthesis in cancer cells using l-NAME, may be a viable therapeutic approach for targeting ovarian cancers and endometrial cancers.

Discussion

Here, our results revealed mechanism behind the interaction between O-ASCs and cancer cells. We found that O-ASCs promoted the growth of both ovarian cancer and endometrial cancer cells through NO. Interestingly, O-ASCs secrete arginine under arginine-deprivation conditions and this secreted arginine was uptaken by cancer cells, thereby increases NO synthesis and cancer cells’ growth rate. Arginine depletion is currently used as a therapy for melanoma and hepatocellular carcinoma (31, 32). We showed that when O-ASC–secreted arginine is depleted (using l-arginase) or when O-ASC–secreted factors induced increased NO synthesis in cancer cells is inhibited (using l-NAME), there is a decline in the growth rate of both ovarian cancer and endometrial cancer cells. It was previously reported by our group that ovarian cancer cells secrete considerable amount of citrulline, thereby indicating high NOS activity and arginine utilization (33). Here, our data showed that ovarian cancer and endometrial cancer cells use arginine produced by O-ASCs and generate citrulline. Remarkably, citrulline secreted by cancer cells increased the adipogenesis of O-ASCs. Thus, our findings propose a previously unexplored metabolic coupling between cancer cells and O-ASCs.

Recent studies proposed metabolic-symbiosis as a reciprocal coupling between cancer cells and its microenvironment (34). In these studies, tumor microenvironment cells, mainly cancer associated fibroblasts, were shown to be in catabolic state, thus generating energy-rich metabolites (such as lactate, glutamine, fatty acids, and other amino acids) that are then used by cancer cells’ mitochondria for OXPHOS (35). However, our findings show that O-ASCs rescue cancer cells loss of growth under arginine-deprivation conditions, by secreting arginine for cell growth/biosynthesis but not for energetic needs. Arginine utilization for NO as a signaling molecule dominated other roles of arginine in cellular functions. As seen in Fig. 3G, growth of cancer cells decreased significantly when arginine was excluded from media and SNAP compensated this decrease induced by arginine deprivation. These results emphasize the crucial role of arginine in NO synthesis.

In contrast with Warburg effect, recent data suggest that cancer cells have healthy mitochondria; however, they have upregulated glycolysis (36). Interestingly, our data suggest that O-ASCs promoted glycolysis in cancer cells by elevating NO synthesis, which has been shown to have inhibitory effects on enzymes involved in mitochondrial respiration. Previous studies showed that NO affects glycolysis through s-nitrosylation of hexokinase (37). Hexokinase converts glucose to glucose-6-phosphate in the first step of glycolysis and is highly expressed in cancer cells (38). Low concentrations of NO (below 100 nmol/L) induce hypoxia-inducible factor 1-α (HIF1α) expression and mimics low oxygen conditions (39). HIF1α, a key regulator of hypoxia, switches energy metabolism from oxidative phosphorylation to glycolysis by regulating glucose transporter-1 (GLUT-1), lactate dehydrogenase (LDH), and pyruvate dehydrogenase (PDH) expression (40). We here showed that O-ASCs positively regulate the Warburg effect by modulating the NO homeostasis. O-ASC–secreted arginine increased NO synthesis in cancer cells that reprogrammed cancer cells by increasing glycolysis and reducing mitochondrial ATP generation. Treating cancer cells with arginine-depleted media showed that reducing NO levels reduced glucose and pyruvate consumption of cells as well as their lactate secretion levels. Remarkably, O-ASCs interaction with cancer cells compensated the reduced levels of metabolites. Consistent with our hypothesis, we found that O-ASCs increased glucose uptake and lactate secretion of cancer cells under arginine-deprivation conditions. O-ASC–modulated ovarian and endometrial cancer cell metabolism via arginine secretion that when uptaken by cancer.

Figure 7.

O-ASCs induce chemoresistance in cancer cells. Stably luciferase transfected cancer cells and O-ASCs were seeded in 96-well plate and cocultured in direct contact for 48 hours before their exposure to different concentrations of paclitaxel along with l-arginase (30 μM/L; A) or l-NAME (20 mmol/L; B). Viability of cancer cells was assessed by addition of luciferin (150 μg/mL) for 1 hour and the corresponding luminescence was measured. C, more patient samples were incorporated to illustrate the increased chemoresistance of cancer cells when directly cocultured with O-ASCs and l-arginase (30 μM/L). D, cancer cells and O-ASCs (ratio 1:3) were directly cocultured in 96-well plates and treated with l-arginase, l-NAME, or their combination for 3 days. Data are expressed for each cell type as the mean ± SE; n = 6, *P < 0.05, †P < 0.01; and ‡P < 0.001. The curves are compared at each point using the Bonferroni test. The Dunnnett method was used to compare multiple groups versus a control group (C).
cells increased NO in these cells. Figure 6E summarizes our results obtained on metabolic coupling between O-ASCs and cancer cells. On the basis of our results, “NO homeostasis” could be a key player in regulating reciprocal communication between O-ASCs and gynecologic cancer cells. The reciprocal communication was observed between cancer cells and O-ASCs, where cancer cells were found to increase glucose metabolism and adipogenesis in O-ASCs.

NO has been known to influence respiratory rates of cancer cells by targeting mitochondrial complexes, complex I and IV (41,42). Previous studies carried out primarily in liver cells showed that NO regulates mitochondrial respiration by targeting terminal enzyme of electron transport chain, cytochrome c oxidase by competing with oxygen (43). Inhibition of complex IV is rapid (milliseconds), reversible, and occurs at low NO concentrations (nmol/L), whereas inhibition of complex I occurs after a constant exposure of higher NO concentrations (44,45). NO’s inhibition of mitochondrial respiration in cancer cells shifts them from oxidative phosphorylation to glycolysis. Here, we showed that arginine deprivation decreases NO, thereby increases OCR of OVCAR429 and HEC-1-A cells (Fig. 5A). O-ASCs decreased OCR of cancer cells by secreting arginine, a substrate for NO synthesis under arginine-deprivation conditions. We demonstrated that NO can shift source of ATP generation in cancer cells cocultured with O-ASCs by increasing glycolytic ATP production and concomitantly decrease mitochondrial contribution toward ATP production (Fig. 6B).

Recent studies have shown that O-ASCs induce chemoresistance in cancer cells (46). Multiple lines of evidence support the link between NO and chemoresistance (47–50). Herein, we show that O-ASCs regulate cancer cells’ response to chemo-drugs through the NO pathway. Inhibition of NO synthesis, sensitized cancer cells cocultured with O-ASCs to paclitaxel (Fig. 7A–C). Furthermore, our studies suggest that combinatorial therapy of depleting arginine using L-arginase, along with inhibiting NO synthase, could disrupt the communication between O-ASCs and cancer cells. Our data present mechanistic insights into O-ASC-mediated metabolic reprogramming in cancer cells and also reciprocal modulation of O-ASCs adipogenesis by cancer cells. Future studies are needed to investigate the therapeutic strategies targeting the impact of O-ASC on cancer initiation and progression. The detailed analysis of altered NO metabolism of cancer cells in the presence of O-ASCs will shed light on the molecular pathways regulated by O-ASCs and thus allow development of targeted therapies linking signaling, transcriptional changes with metabolic signatures linking obesity with cancer.

Disclosure of Potential Conflicts of Interest
No potential conflicts of interest were disclosed.

Authors’ Contributions
Conception and design: B. Salimian Rizi, C. Caneba, D. Nagrath
Development of methodology: B. Salimian Rizi, D. Nagrath
Acquisition of data (provided animals, acquired and managed patients, provided facilities, etc.): B. Salimian Rizi, A.W. Nabiyar, X. Liu, K. Chen, D. Nagrath
Analysis and interpretation of data (e.g., statistical analysis, biostatistics, computational analysis): B. Salimian Rizi, A.W. Nabiyar, A. Klop, D. Nagrath
Writing, review, and/or revision of the manuscript: B. Salimian Rizi, A. Klop, D. Nagrath
Administrative, technical, or material support (i.e., reporting or organizing data, constructing databases): B. Salimian Rizi, A. Nowicka
Study supervision: B. Salimian Rizi, D. Nagrath
Other (discussions): A. Nowicka

Grant Support
This work was made possible, in part, through support from the Ken Kennedy Institute for Information Technology at Rice University to D. Nagrath under the Collaborative Advances in Biomedical Computing 2011 seed funding program supported by the John and Ann Doerr Fund for the Computational Biomedicine.

The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked advertisement in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

Received May 6, 2014; revised October 6, 2014; accepted October 24, 2014; published OnlineFirst November 25, 2014.

References

Nitric Oxide Mediates Metabolic Coupling of Omentum-Derived Adipose Stroma to Ovarian and Endometrial Cancer Cells

Bahar Salimian Rizi, Christine Caneba, Aleksandra Nowicka, et al.


Updated version
Access the most recent version of this article at:
doi:10.1158/0008-5472.CAN-14-1337

Supplementary Material
Access the most recent supplemental material at:
http://cancerres.aacrjournals.org/content/suppl/2014/11/26/0008-5472.CAN-14-1337.DC1

Cited articles
This article cites 50 articles, 17 of which you can access for free at:
http://cancerres.aacrjournals.org/content/75/2/456.full.html#ref-list-1

Citing articles
This article has been cited by 1 HighWire-hosted articles. Access the articles at:
/content/75/2/456.full.html#related-urls

E-mail alerts
Sign up to receive free email-alerts related to this article or journal.

Reprints and Subscriptions
To order reprints of this article or to subscribe to the journal, contact the AACR Publications Department at pubs@aacr.org.

Permissions
To request permission to re-use all or part of this article, contact the AACR Publications Department at permissions@aacr.org.